الفهرس 
OVARIAN CANCEROnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Our results suggest clearly that inclusion of YKL-40 to the current standard tests for diagnosis of early and for detection of recurrent ovarian cancer would improve the ability to identify patients who might be missed by current diagnostic strategies and thus might provide a better therapeutic outcome.
• We therefore recommend:
1- Further research studies to be conducted on the group of subjects with YKL-40 levels between 120 to 200 ng/ml and correlating them to stage I ovarian cancer during screening of high risk individuals.
2- Assessment of the ability of YKL-40 to predict the outcome of patients with different tumor grades of ovarian cancer.
3- Determination of alternative cutoff values of YKL-40 in different histopathological types of ovarian cancer.
4- Further horizontal research studies to be done for assessment of the ability of YKL-40 to predict the response to primary chemotherapy in ovarian cancer patients.